Palmitoylethanolamide (PEA) has been emerging as a safe and well tolerated analgesic, anti-inflammatory and neuroprotective mediator, acting at several molecular targets in the nervous system. PEA is present in foods, as egg yolk, corn, peanut and soy oil. It is synthesized from lipid components of cellular membranes and can be found in high concentrations in brain tissues. In this study, we evaluated the effects of a chronic (6 months) administration of ultra-micronized PEA on cognitive decline in transgenic Tg2576 (Tg) mice expressing mutant APP. When aged, Tg mice develop accumulation of amyloid peptide and amyloid plaques in the brain, as well as cognitive deficits, representing thus an animal model of AD. PEA administration was performed via a subcutaneous delivery system in Tg mice and wild-type control group (from 6 to 12 months of age). PEA effects on behavior were observed longitudinally in a pre-symptomatic phase (3 months), a mild-symptomatic phase (6.5 months) and a full-symptomatic phase (11-12 months). Behavioral assessment was performed by using the following validated tests: Elevated Plus Maze, Rotarod Test, Y-Maze Spontaneous Alternation Test, Novel Object Recognition Test, Tail Suspension Test and Morris Water Maze. PEA administration restored the novelty recognition memory of Tg mice during the full-symptomatic phase. PEA was able to counteract hippocampal- dependent mnesic deficits, suggesting the therapeutic potential for the early treatment of AD. Further in progress analyses involve histological evaluation of dendritic branching, spine number, amyloid plaques and glial reactivity in the hippocampal CA1. This research is aimed to increase knowledge of the effects of PEA as a safe and low-cost nutraceutical tool useful to improve quality of life in AD.

Chronic administration of palmitoylethanolamide counteracts cognitive decline in Tg2576 Mice / Decandia, Davide; Sacchetti, Stefano; Landolfo, Eugenia; Massa, Greta; Allegretti, Elena; Giacovazzo, Giacomo; Cutuli, Debora. - (2022). (Intervento presentato al convegno BraYn 2022 tenutosi a Rome).

Chronic administration of palmitoylethanolamide counteracts cognitive decline in Tg2576 Mice

Davide Decandia;Stefano Sacchetti;Eugenia Landolfo;Greta Massa;Elena Allegretti;Giacomo Giacovazzo;Debora Cutuli
2022

Abstract

Palmitoylethanolamide (PEA) has been emerging as a safe and well tolerated analgesic, anti-inflammatory and neuroprotective mediator, acting at several molecular targets in the nervous system. PEA is present in foods, as egg yolk, corn, peanut and soy oil. It is synthesized from lipid components of cellular membranes and can be found in high concentrations in brain tissues. In this study, we evaluated the effects of a chronic (6 months) administration of ultra-micronized PEA on cognitive decline in transgenic Tg2576 (Tg) mice expressing mutant APP. When aged, Tg mice develop accumulation of amyloid peptide and amyloid plaques in the brain, as well as cognitive deficits, representing thus an animal model of AD. PEA administration was performed via a subcutaneous delivery system in Tg mice and wild-type control group (from 6 to 12 months of age). PEA effects on behavior were observed longitudinally in a pre-symptomatic phase (3 months), a mild-symptomatic phase (6.5 months) and a full-symptomatic phase (11-12 months). Behavioral assessment was performed by using the following validated tests: Elevated Plus Maze, Rotarod Test, Y-Maze Spontaneous Alternation Test, Novel Object Recognition Test, Tail Suspension Test and Morris Water Maze. PEA administration restored the novelty recognition memory of Tg mice during the full-symptomatic phase. PEA was able to counteract hippocampal- dependent mnesic deficits, suggesting the therapeutic potential for the early treatment of AD. Further in progress analyses involve histological evaluation of dendritic branching, spine number, amyloid plaques and glial reactivity in the hippocampal CA1. This research is aimed to increase knowledge of the effects of PEA as a safe and low-cost nutraceutical tool useful to improve quality of life in AD.
2022
BraYn 2022
04 Pubblicazione in atti di convegno::04d Abstract in atti di convegno
Chronic administration of palmitoylethanolamide counteracts cognitive decline in Tg2576 Mice / Decandia, Davide; Sacchetti, Stefano; Landolfo, Eugenia; Massa, Greta; Allegretti, Elena; Giacovazzo, Giacomo; Cutuli, Debora. - (2022). (Intervento presentato al convegno BraYn 2022 tenutosi a Rome).
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1669443
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact